Confirmation of Obama's HHS Sec choice still on hold

23 April 2009

Support for abortion and for research on the comparative effectiveness of disease treatments could be two stumbling blocks to the confirmation  of US President Barack Obama's choice of Kathleen Sebelius (Democrat  Governor, Kansas) for the post of Secretary of Health and Human Services  (Marketletter March 9).

This is the last Cabinet appointment still to be cleared through the  normal congressional system. In a Senate Finance Committee meeting,  eight of 10 Republican members opposed Gov Sebelius' nomination,  although there was overall support in a 15-to-eight vote. A full Senate  vote is now expected next week.

One of the opposers was Senator Jon Kyl (Republican, Arizona) who,  according to the Washington Post, fears that her evidence-based  approach, coupled with information on price, could lead to rationing of  health care. Senate Minority Leader Mitch McConnell (Republican,  Kentucky) objected, saying that lawmakers need more time to consider her  "fairly contentious" selection.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight